市場調査レポート

商品コード

1365684

デジタルバイオマーカー市場：タイプ別、用途別、診療行為別、エンドユーザー別：世界の機会分析と産業予測、2023～2032年

Digital Biomarkers Market By Type, By Application, By Clinical Practice, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2023年07月01日 | 発行: Allied Market Research

| ページ情報: 英文 438 Pages | 納期: 2～3営業日

価格

PDF (Single User License)

USD 5,730 898,234円

レポートPDFを1つのPCでご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は1回だけ可能です。印刷したレポートの利用もPDFのライセンス保持者になります。回覧のための複製も原則NGです。

PDF (5-user License)

USD 6,450 1,011,102円

レポートPDFを5名でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は5回可能です。印刷したレポートの利用もPDFのライセンス保持者5名となります。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,504,896円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

デジタルバイオマーカー市場の2022年の市場規模は21億米ドルで、2023年から2032年までのCAGRは21.3％で成長し、2032年には147億米ドルに達すると予測されています。

デジタルバイオマーカーは、携帯型、装着型、埋め込み型、摂取型などのデジタル機器を使用して取得・評価される測定可能な生理学的・行動学的データとして特徴付けられます。収集された情報は、多くの場合、健康に関連する結果の予測、影響、説明に使用されます。デジタルバイオマーカーは、治療的意義のある事実データを収集する新たな機会を提供します。この革新的なオープンアクセスの学際的アプローチは、情報学、工学、生物医学、規制科学、コンピュータ科学を統合します。

デジタルバイオマーカー市場の成長を牽引するのは、デジタルバイオマーカーを製造する市場参入企業の存在感の高さと、心血管疾患、呼吸器疾患、精神疾患、神経疾患などの慢性疾患の有病率の増加です。デジタルバイオマーカーは、幅広い疾患や健康状態のモニタリングに使用されます。デジタルバイオマーカーは、心拍数、心拍変動、血圧、その他の関連パラメータをモニターし、高血圧、不整脈、心不全などの心血管疾患のリスクを評価することを目的としています。これらのバイオマーカーは、睡眠、活動レベル、社会的交流、発話特性のパターンを分析することで、うつ病、不安障害、双極性障害などの精神的健康状態の評価やモニタリングに活用できます。

さらに、デジタルバイオマーカーは、パーキンソン病、アルツハイマー病、多発性硬化症、てんかんのような神経疾患のモニタリングや管理に役立ちます。これらのバイオマーカーには、歩行分析、振戦頻度、認知パフォーマンス、睡眠障害などが含まれます。デジタルバイオマーカーは、慢性疼痛患者の疼痛レベル、活動パターン、睡眠の質、気分の変動を追跡・分析するのに役立ち、個別化された疼痛管理アプローチを支援します。

例えば、英国心臓財団（British Heart Foundation）によると、2022年には英国で約113万9,140人が心臓・循環器系疾患に罹患していると報告されています。同じ出典によると、2022年には、英国で男性約65万681人、女性約48万8,320人が心臓・循環器系疾患に罹患しています。このように、慢性疾患の増加は、デジタルバイオマーカーの需要を促進し、市場の成長を後押しすると予想されます。

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - 慢性疾患の増加
  - 高齢者人口の増加
  - デジタルバイオマーカーがもたらすメリット
- 抑制要因
  - データセキュリティの問題
- 機会
  - 市場参入企業による製品承認数と製品上市数の増加
  - 市場参入企業の高い存在感
COVID-19市場への影響分析

第4章デジタルバイオマーカー市場：タイプ別

概要
ウェアラブル
モバイルアプリケーション
その他

第5章デジタルバイオマーカー市場：用途別

概要
心血管疾患
糖尿病
神経疾患
呼吸器疾患
その他

第6章デジタルバイオマーカー市場：診療行為別

概要
モニタリング
診断
予後予測

第7章デジタルバイオマーカー市場：エンドユーザー別

概要
医療提供者
医療消費者
その他

第8章デジタルバイオマーカー市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他
ラテンアメリカ・中東・アフリカ
- ブラジル
- 南アフリカ
- サウジアラビア
- その他

第9章競争情勢

イントロダクション
主要成功戦略
主要10社の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第10章企業プロファイル

ActiGraph LLC
Verily Life Sciences LLC
AliveCor
Koneksahealth
Amgen Inc.
Empatica
Sonde Health, Inc.
Clario
Feel Therapeutics
Brainomix

図表

LIST OF TABLES

TABLE 01. GLOBAL DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. DIGITAL BIOMARKERS MARKET FOR WEARABLE, BY REGION, 2022-2032 ($MILLION)
TABLE 03. DIGITAL BIOMARKERS MARKET FOR MOBILE APPLICATION, BY REGION, 2022-2032 ($MILLION)
TABLE 04. DIGITAL BIOMARKERS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 06. DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR DISEASE, BY REGION, 2022-2032 ($MILLION)
TABLE 07. DIGITAL BIOMARKERS MARKET FOR DIABETES, BY REGION, 2022-2032 ($MILLION)
TABLE 08. DIGITAL BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. DIGITAL BIOMARKERS MARKET FOR RESPIRATORY DISEASE, BY REGION, 2022-2032 ($MILLION)
TABLE 10. DIGITAL BIOMARKERS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 12. DIGITAL BIOMARKERS MARKET FOR MONITORING, BY REGION, 2022-2032 ($MILLION)
TABLE 13. DIGITAL BIOMARKERS MARKET FOR DIAGNOSTIC, BY REGION, 2022-2032 ($MILLION)
TABLE 14. DIGITAL BIOMARKERS MARKET FOR PROGNOSTIC, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GLOBAL DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 16. DIGITAL BIOMARKERS MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 17. DIGITAL BIOMARKERS MARKET FOR HEALTHCARE CONSUMERS, BY REGION, 2022-2032 ($MILLION)
TABLE 18. DIGITAL BIOMARKERS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 19. DIGITAL BIOMARKERS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 20. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 21. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 22. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 23. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 24. NORTH AMERICA DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 25. U.S. DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 26. U.S. DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 27. U.S. DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 28. U.S. DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 29. CANADA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 30. CANADA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 31. CANADA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 32. CANADA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 33. MEXICO DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 34. MEXICO DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 35. MEXICO DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 36. MEXICO DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 37. EUROPE DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 38. EUROPE DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 39. EUROPE DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 40. EUROPE DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 41. EUROPE DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 42. GERMANY DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 43. GERMANY DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 44. GERMANY DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 45. GERMANY DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 46. FRANCE DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 47. FRANCE DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 48. FRANCE DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 49. FRANCE DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 50. UK DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 51. UK DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 52. UK DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 53. UK DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 54. ITALY DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 55. ITALY DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 56. ITALY DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 57. ITALY DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 58. SPAIN DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 59. SPAIN DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 60. SPAIN DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 61. SPAIN DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 62. REST OF EUROPE DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 63. REST OF EUROPE DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 64. REST OF EUROPE DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 65. REST OF EUROPE DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 66. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 67. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 68. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 69. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 70. ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 71. JAPAN DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 72. JAPAN DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 73. JAPAN DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 74. JAPAN DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 75. CHINA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 76. CHINA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 77. CHINA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 78. CHINA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 79. INDIA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 80. INDIA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 81. INDIA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 82. INDIA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 83. AUSTRALIA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 84. AUSTRALIA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 85. AUSTRALIA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 86. AUSTRALIA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 87. SOUTH KOREA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 88. SOUTH KOREA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 89. SOUTH KOREA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 90. SOUTH KOREA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 91. REST OF ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 92. REST OF ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 93. REST OF ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 94. REST OF ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 95. LAMEA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 96. LAMEA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 97. LAMEA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 98. LAMEA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 99. LAMEA DIGITAL BIOMARKERS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 100. BRAZIL DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 101. BRAZIL DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 102. BRAZIL DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 103. BRAZIL DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 104. SOUTH AFRICA, DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 105. SOUTH AFRICA, DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 106. SOUTH AFRICA, DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 107. SOUTH AFRICA, DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 108. SAUDI ARABIA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 109. SAUDI ARABIA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 110. SAUDI ARABIA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 111. SAUDI ARABIA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 112. REST OF LAMEA DIGITAL BIOMARKERS MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 113. REST OF LAMEA DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 114. REST OF LAMEA DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022-2032 ($MILLION)
TABLE 115. REST OF LAMEA DIGITAL BIOMARKERS MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 116. ACTIGRAPH LLC: KEY EXECUTIVES
TABLE 117. ACTIGRAPH LLC: COMPANY SNAPSHOT
TABLE 118. ACTIGRAPH LLC: PRODUCT SEGMENTS
TABLE 119. ACTIGRAPH LLC: SERVICE SEGMENTS
TABLE 120. ACTIGRAPH LLC: PRODUCT PORTFOLIO
TABLE 121. ACTIGRAPH LLC: KEY STRATERGIES
TABLE 122. VERILY LIFE SCIENCES LLC: KEY EXECUTIVES
TABLE 123. VERILY LIFE SCIENCES LLC: COMPANY SNAPSHOT
TABLE 124. VERILY LIFE SCIENCES LLC: PRODUCT SEGMENTS
TABLE 125. VERILY LIFE SCIENCES LLC: PRODUCT PORTFOLIO
TABLE 126. ALIVECOR: KEY EXECUTIVES
TABLE 127. ALIVECOR: COMPANY SNAPSHOT
TABLE 128. ALIVECOR: PRODUCT SEGMENTS
TABLE 129. ALIVECOR: SERVICE SEGMENTS
TABLE 130. ALIVECOR: PRODUCT PORTFOLIO
TABLE 131. ALIVECOR: KEY STRATERGIES
TABLE 132. KONEKSAHEALTH: KEY EXECUTIVES
TABLE 133. KONEKSAHEALTH: COMPANY SNAPSHOT
TABLE 134. KONEKSAHEALTH: PRODUCT SEGMENTS
TABLE 135. KONEKSAHEALTH: PRODUCT PORTFOLIO
TABLE 136. KONEKSAHEALTH: KEY STRATERGIES
TABLE 137. AMGEN INC.: KEY EXECUTIVES
TABLE 138. AMGEN INC.: COMPANY SNAPSHOT
TABLE 139. AMGEN INC.: PRODUCT SEGMENTS
TABLE 140. AMGEN INC.: PRODUCT PORTFOLIO
TABLE 141. EMPATICA: KEY EXECUTIVES
TABLE 142. EMPATICA: COMPANY SNAPSHOT
TABLE 143. EMPATICA: PRODUCT SEGMENTS
TABLE 144. EMPATICA: PRODUCT PORTFOLIO
TABLE 145. EMPATICA: KEY STRATERGIES
TABLE 146. SONDE HEALTH, INC.: KEY EXECUTIVES
TABLE 147. SONDE HEALTH, INC.: COMPANY SNAPSHOT
TABLE 148. SONDE HEALTH, INC.: PRODUCT SEGMENTS
TABLE 149. SONDE HEALTH, INC.: PRODUCT PORTFOLIO
TABLE 150. CLARIO: KEY EXECUTIVES
TABLE 151. CLARIO: COMPANY SNAPSHOT
TABLE 152. CLARIO: PRODUCT SEGMENTS
TABLE 153. CLARIO: PRODUCT PORTFOLIO
TABLE 154. FEEL THERAPEUTICS: KEY EXECUTIVES
TABLE 155. FEEL THERAPEUTICS: COMPANY SNAPSHOT
TABLE 156. FEEL THERAPEUTICS: PRODUCT SEGMENTS
TABLE 157. FEEL THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 158. FEEL THERAPEUTICS: KEY STRATERGIES
TABLE 159. BRAINOMIX: KEY EXECUTIVES
TABLE 160. BRAINOMIX: COMPANY SNAPSHOT
TABLE 161. BRAINOMIX: PRODUCT SEGMENTS
TABLE 162. BRAINOMIX: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. DIGITAL BIOMARKERS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF DIGITAL BIOMARKERS MARKET, 2022-2032
FIGURE 03. DIGITAL BIOMARKERS MARKET,2022-2032
FIGURE 04. TOP INVESTMENT POCKETS IN DIGITAL BIOMARKERS MARKET (2023-2032)
FIGURE 05. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 06. LOW THREAT OF NEW ENTRANTS
FIGURE 07. LOW THREAT OF SUBSTITUTES
FIGURE 08. LOW INTENSITY OF RIVALRY
FIGURE 09. LOW BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL DIGITAL BIOMARKERS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. DIGITAL BIOMARKERS MARKET, BY TYPE, 2022(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR WEARABLE, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR MOBILE APPLICATION, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. DIGITAL BIOMARKERS MARKET, BY APPLICATION, 2022(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR CARDIOVASCULAR DISEASE, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR DIABETES, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR RESPIRATORY DISEASE, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE, 2022(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR MONITORING, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR DIAGNOSTIC, BY COUNTRY 2022 AND 2032(%)
FIGURE 24. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR PROGNOSTIC, BY COUNTRY 2022 AND 2032(%)
FIGURE 25. DIGITAL BIOMARKERS MARKET, BY END USER, 2022(%)
FIGURE 26. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR HEALTHCARE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 27. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR HEALTHCARE CONSUMERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 28. COMPARATIVE SHARE ANALYSIS OF DIGITAL BIOMARKERS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 29. DIGITAL BIOMARKERS MARKET BY REGION, 2022(%)
FIGURE 30. U.S. DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 31. CANADA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 32. MEXICO DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 33. GERMANY DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 34. FRANCE DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 35. UK DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 36. ITALY DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 37. SPAIN DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 38. REST OF EUROPE DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 39. JAPAN DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 40. CHINA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 41. INDIA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 42. AUSTRALIA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 43. SOUTH KOREA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 44. REST OF ASIA-PACIFIC DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 45. BRAZIL DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 46. SOUTH AFRICA, DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 47. SAUDI ARABIA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 48. REST OF LAMEA DIGITAL BIOMARKERS MARKET, 2022-2032 ($MILLION)
FIGURE 49. TOP WINNING STRATEGIES, BY YEAR
FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 52. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 53. COMPETITIVE DASHBOARD
FIGURE 54. COMPETITIVE HEATMAP: DIGITAL BIOMARKERS MARKET
FIGURE 55. TOP PLAYER POSITIONING, 2022
FIGURE 56. AMGEN INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 57. AMGEN INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 58. AMGEN INC.: REVENUE SHARE BY SEGMENT, 2022 (%)

Product Code: A132422

According to a new report published by Allied Market Research, titled, "Digital Biomarkers Market," The digital biomarkers market was valued at $2.1 billion in 2022, and is estimated to reach $14.7 billion by 2032, growing at a CAGR of 21.3% from 2023 to 2032.

Digital biomarkers are characterized as measurable physiological and behavioral data that are obtained and assessed using digital devices such as portable, wearable, implantable, or ingestible ones. The information gathered is often used to forecast, affect, or explain outcomes connected to health. Digital biomarkers offer another chance to gather factual data that has therapeutic significance. This innovative open-access multidisciplinary approach unites informatics, engineering, biomedicine, regulatory science, and computer science.

The digital biomarkers market growth is driven by high presence of market players who manufacture digital biomarkers and increase in prevalence of chronic diseases such as cardiovascular diseases, respiratory diseases, psychiatric diseases, neurological diseases, and others. Digital biomarkers are used to monitor a wide range of diseases and health conditions. Digital biomarkers aim to monitor heart rate, heart rate variability, blood pressure, and other related parameters to assess the risk of cardiovascular diseases such as hypertension, arrhythmias, and heart failure. These biomarkers can be utilized to assess and monitor mental health conditions such as depression, anxiety, and bipolar disorder by analyzing patterns in sleep, activity levels, social interactions, and speech characteristics.

Moreover, digital biomarkers can aid in the monitoring and management of neurological conditions like Parkinson's disease, Alzheimer's disease, multiple sclerosis, and epilepsy. These biomarkers can include gait analysis, tremor frequency, cognitive performance, and sleep disturbances. Digital biomarkers can help track and analyze pain levels, activity patterns, sleep quality, and mood fluctuations in patients with chronic pain conditions, assisting in personalized pain management approaches.

For instance, according to the British Heart Foundation, in 2022, around 1,139,140 people were reported to have been suffering from heart and circulatory diseases in the UK. As per the same source, in 2022, around 650,681 male and 488,320 female population were suffering from heart and circulatory diseases in the UK. Thus, rise in number of chronic diseases is anticipated to drive the demand for digital biomarker and boost the growth of the market.

In addition, geriatric population is more susceptible to chronic diseases such as cardiovascular diseases, neurological disorders, respiratory diseases, and others. Thus, increase in the number of geriatric populations is expected to witness growth in prevalence of neurological diseases such as Alzheimer's dementia (AD). Therefore, this is expected to increase the demand for digital biomarkers and boost the growth of the market. According to World Health Organization, (WHO), population aged 60 years and over were expected to increase from 1 billion in 2020 to 1.4 billion in 2022 globally. By 2050, the global population of people aged 60 years and older is expected to increase by two-fold. The number of people aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.

Moreover, according to Alzheimer's Association, in 2022, an estimated 6.5 million Americans aged 65 and older were reported to have been living with Alzheimer's dementia (AD). This number is projected to grow to 13.8 million by 2060. On the other hand, data privacy and security concerns, and lack of awareness is anticipated to hamper the growth of the market. However, increase in demand for digital medical devices in the developed countries such as U.S., Canada, and Germany and growth opportunities in emerging markets are expected to create immense opportunities for the digital biomarkers market during the forecast period.

The digital biomarkers market is segmented on the basis of type, application, end user and region. By type the market is divided into wearable, mobile application, software, and others (sensor, card, and implantable). By application, the market is classified into cardiovascular disease, sleep & movement disease, neurological disorders, and others. (respiratory diseases, diabetes, psychiatric and musculoskeletal disorders). By clinical practice, the market is classified into monitoring, diagnostic and prognostic. By end user, the market is divided into healthcare companies, hospitals, and others (payers and patients)

Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Major key players that operate in the global digital biomarkers market are ActiGraph LLC, Verily Life Sciences, Alivecor, koneksahealth, Amgen, Brainomix, Feel Therapeutics, Sonde Health, Inc., Empatica, Clario. Key players operating in the market have adopted product approval, product launch, acquisition and agreement as their key strategies to expand their digital biomarkers market share.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the digital biomarkers market analysis from 2022 to 2032 to identify the prevailing digital biomarkers market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the digital biomarkers market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global digital biomarkers market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)

Product Benchmarking / Product specification and applications
Upcoming/New Entrant by Regions
New Product Development/ Product Matrix of Key Players
Patient/epidemiology data at country, region, global level
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
SWOT Analysis

Key Market Segments

By Type

Wearable
Mobile Application
Others

By Application

Neurological Disorders
Respiratory Disease
Others
Cardiovascular Disease
Diabetes

By Clinical Practice

Monitoring
Diagnostic
Prognostic

By End User

Healthcare Providers
Healthcare Consumers
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- South Africa,
- Saudi Arabia
- Rest of LAMEA

Key Market Players:

ActiGraph LLC
AliveCor
Amgen Inc.
Brainomix
Clario
Empatica
Feel Therapeutics
Koneksahealth
Sonde Health, Inc.
Verily Life Sciences LLC

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in prevalence of chronic diseases
  - 3.4.1.2. Increase in number of geriatric populations
  - 3.4.1.3. Benefits associated with digital biomarkers

3.4.2. Restraints
- 3.4.2.1. Data security issue

3.4.3. Opportunities
- 3.4.3.1. Rise in number of product approvals and products launches by market players.
- 3.4.3.2. High presence of market players

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: DIGITAL BIOMARKERS MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Wearable
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Mobile Application
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country
4.4. Others
- 4.4.1. Key market trends, growth factors and opportunities
- 4.4.2. Market size and forecast, by region
- 4.4.3. Market share analysis by country

CHAPTER 5: DIGITAL BIOMARKERS MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Cardiovascular Disease
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Diabetes
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Neurological Disorders
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Respiratory Disease
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
5.6. Others
- 5.6.1. Key market trends, growth factors and opportunities
- 5.6.2. Market size and forecast, by region
- 5.6.3. Market share analysis by country

CHAPTER 6: DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Monitoring
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. Diagnostic
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Prognostic
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: DIGITAL BIOMARKERS MARKET, BY END USER

7.1. Overview
- 7.1.1. Market size and forecast
7.2. Healthcare Providers
- 7.2.1. Key market trends, growth factors and opportunities
- 7.2.2. Market size and forecast, by region
- 7.2.3. Market share analysis by country
7.3. Healthcare Consumers
- 7.3.1. Key market trends, growth factors and opportunities
- 7.3.2. Market size and forecast, by region
- 7.3.3. Market share analysis by country
7.4. Others
- 7.4.1. Key market trends, growth factors and opportunities
- 7.4.2. Market size and forecast, by region
- 7.4.3. Market share analysis by country

CHAPTER 8: DIGITAL BIOMARKERS MARKET, BY REGION

8.1. Overview
- 8.1.1. Market size and forecast By Region
8.2. North America
- 8.2.1. Key trends and opportunities
- 8.2.2. Market size and forecast, by Type
- 8.2.3. Market size and forecast, by Application
- 8.2.4. Market size and forecast, by Clinical Practice
- 8.2.5. Market size and forecast, by End User
- 8.2.6. Market size and forecast, by country
  - 8.2.6.1. U.S.
  - 8.2.6.1.1. Key market trends, growth factors and opportunities
  - 8.2.6.1.2. Market size and forecast, by Type
  - 8.2.6.1.3. Market size and forecast, by Application
  - 8.2.6.1.4. Market size and forecast, by Clinical Practice
  - 8.2.6.1.5. Market size and forecast, by End User
  - 8.2.6.2. Canada
  - 8.2.6.2.1. Key market trends, growth factors and opportunities
  - 8.2.6.2.2. Market size and forecast, by Type
  - 8.2.6.2.3. Market size and forecast, by Application
  - 8.2.6.2.4. Market size and forecast, by Clinical Practice
  - 8.2.6.2.5. Market size and forecast, by End User
  - 8.2.6.3. Mexico
  - 8.2.6.3.1. Key market trends, growth factors and opportunities
  - 8.2.6.3.2. Market size and forecast, by Type
  - 8.2.6.3.3. Market size and forecast, by Application
  - 8.2.6.3.4. Market size and forecast, by Clinical Practice
  - 8.2.6.3.5. Market size and forecast, by End User
8.3. Europe
- 8.3.1. Key trends and opportunities
- 8.3.2. Market size and forecast, by Type
- 8.3.3. Market size and forecast, by Application
- 8.3.4. Market size and forecast, by Clinical Practice
- 8.3.5. Market size and forecast, by End User
- 8.3.6. Market size and forecast, by country
  - 8.3.6.1. Germany
  - 8.3.6.1.1. Key market trends, growth factors and opportunities
  - 8.3.6.1.2. Market size and forecast, by Type
  - 8.3.6.1.3. Market size and forecast, by Application
  - 8.3.6.1.4. Market size and forecast, by Clinical Practice
  - 8.3.6.1.5. Market size and forecast, by End User
  - 8.3.6.2. France
  - 8.3.6.2.1. Key market trends, growth factors and opportunities
  - 8.3.6.2.2. Market size and forecast, by Type
  - 8.3.6.2.3. Market size and forecast, by Application
  - 8.3.6.2.4. Market size and forecast, by Clinical Practice
  - 8.3.6.2.5. Market size and forecast, by End User
  - 8.3.6.3. UK
  - 8.3.6.3.1. Key market trends, growth factors and opportunities
  - 8.3.6.3.2. Market size and forecast, by Type
  - 8.3.6.3.3. Market size and forecast, by Application
  - 8.3.6.3.4. Market size and forecast, by Clinical Practice
  - 8.3.6.3.5. Market size and forecast, by End User
  - 8.3.6.4. Italy
  - 8.3.6.4.1. Key market trends, growth factors and opportunities
  - 8.3.6.4.2. Market size and forecast, by Type
  - 8.3.6.4.3. Market size and forecast, by Application
  - 8.3.6.4.4. Market size and forecast, by Clinical Practice
  - 8.3.6.4.5. Market size and forecast, by End User
  - 8.3.6.5. Spain
  - 8.3.6.5.1. Key market trends, growth factors and opportunities
  - 8.3.6.5.2. Market size and forecast, by Type
  - 8.3.6.5.3. Market size and forecast, by Application
  - 8.3.6.5.4. Market size and forecast, by Clinical Practice
  - 8.3.6.5.5. Market size and forecast, by End User
  - 8.3.6.6. Rest of Europe
  - 8.3.6.6.1. Key market trends, growth factors and opportunities
  - 8.3.6.6.2. Market size and forecast, by Type
  - 8.3.6.6.3. Market size and forecast, by Application
  - 8.3.6.6.4. Market size and forecast, by Clinical Practice
  - 8.3.6.6.5. Market size and forecast, by End User
8.4. Asia-Pacific
- 8.4.1. Key trends and opportunities
- 8.4.2. Market size and forecast, by Type
- 8.4.3. Market size and forecast, by Application
- 8.4.4. Market size and forecast, by Clinical Practice
- 8.4.5. Market size and forecast, by End User
- 8.4.6. Market size and forecast, by country
  - 8.4.6.1. Japan
  - 8.4.6.1.1. Key market trends, growth factors and opportunities
  - 8.4.6.1.2. Market size and forecast, by Type
  - 8.4.6.1.3. Market size and forecast, by Application
  - 8.4.6.1.4. Market size and forecast, by Clinical Practice
  - 8.4.6.1.5. Market size and forecast, by End User
  - 8.4.6.2. China
  - 8.4.6.2.1. Key market trends, growth factors and opportunities
  - 8.4.6.2.2. Market size and forecast, by Type
  - 8.4.6.2.3. Market size and forecast, by Application
  - 8.4.6.2.4. Market size and forecast, by Clinical Practice
  - 8.4.6.2.5. Market size and forecast, by End User
  - 8.4.6.3. India
  - 8.4.6.3.1. Key market trends, growth factors and opportunities
  - 8.4.6.3.2. Market size and forecast, by Type
  - 8.4.6.3.3. Market size and forecast, by Application
  - 8.4.6.3.4. Market size and forecast, by Clinical Practice
  - 8.4.6.3.5. Market size and forecast, by End User
  - 8.4.6.4. Australia
  - 8.4.6.4.1. Key market trends, growth factors and opportunities
  - 8.4.6.4.2. Market size and forecast, by Type
  - 8.4.6.4.3. Market size and forecast, by Application
  - 8.4.6.4.4. Market size and forecast, by Clinical Practice
  - 8.4.6.4.5. Market size and forecast, by End User
  - 8.4.6.5. South Korea
  - 8.4.6.5.1. Key market trends, growth factors and opportunities
  - 8.4.6.5.2. Market size and forecast, by Type
  - 8.4.6.5.3. Market size and forecast, by Application
  - 8.4.6.5.4. Market size and forecast, by Clinical Practice
  - 8.4.6.5.5. Market size and forecast, by End User
  - 8.4.6.6. Rest of Asia-Pacific
  - 8.4.6.6.1. Key market trends, growth factors and opportunities
  - 8.4.6.6.2. Market size and forecast, by Type
  - 8.4.6.6.3. Market size and forecast, by Application
  - 8.4.6.6.4. Market size and forecast, by Clinical Practice
  - 8.4.6.6.5. Market size and forecast, by End User
8.5. LAMEA
- 8.5.1. Key trends and opportunities
- 8.5.2. Market size and forecast, by Type
- 8.5.3. Market size and forecast, by Application
- 8.5.4. Market size and forecast, by Clinical Practice
- 8.5.5. Market size and forecast, by End User
- 8.5.6. Market size and forecast, by country
  - 8.5.6.1. Brazil
  - 8.5.6.1.1. Key market trends, growth factors and opportunities
  - 8.5.6.1.2. Market size and forecast, by Type
  - 8.5.6.1.3. Market size and forecast, by Application
  - 8.5.6.1.4. Market size and forecast, by Clinical Practice
  - 8.5.6.1.5. Market size and forecast, by End User
  - 8.5.6.2. South Africa,
  - 8.5.6.2.1. Key market trends, growth factors and opportunities
  - 8.5.6.2.2. Market size and forecast, by Type
  - 8.5.6.2.3. Market size and forecast, by Application
  - 8.5.6.2.4. Market size and forecast, by Clinical Practice
  - 8.5.6.2.5. Market size and forecast, by End User
  - 8.5.6.3. Saudi Arabia
  - 8.5.6.3.1. Key market trends, growth factors and opportunities
  - 8.5.6.3.2. Market size and forecast, by Type
  - 8.5.6.3.3. Market size and forecast, by Application
  - 8.5.6.3.4. Market size and forecast, by Clinical Practice
  - 8.5.6.3.5. Market size and forecast, by End User
  - 8.5.6.4. Rest of LAMEA
  - 8.5.6.4.1. Key market trends, growth factors and opportunities
  - 8.5.6.4.2. Market size and forecast, by Type
  - 8.5.6.4.3. Market size and forecast, by Application
  - 8.5.6.4.4. Market size and forecast, by Clinical Practice
  - 8.5.6.4.5. Market size and forecast, by End User

CHAPTER 9: COMPETITIVE LANDSCAPE

9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Player
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022

CHAPTER 10: COMPANY PROFILES

10.1. ActiGraph LLC
- 10.1.1. Company overview
- 10.1.2. Key Executives
- 10.1.3. Company snapshot
- 10.1.4. Operating business segments
- 10.1.5. Product portfolio
- 10.1.6. Key strategic moves and developments
10.2. Verily Life Sciences LLC
- 10.2.1. Company overview
- 10.2.2. Key Executives
- 10.2.3. Company snapshot
- 10.2.4. Operating business segments
- 10.2.5. Product portfolio
10.3. AliveCor
- 10.3.1. Company overview
- 10.3.2. Key Executives
- 10.3.3. Company snapshot
- 10.3.4. Operating business segments
- 10.3.5. Product portfolio
- 10.3.6. Key strategic moves and developments
10.4. Koneksahealth
- 10.4.1. Company overview
- 10.4.2. Key Executives
- 10.4.3. Company snapshot
- 10.4.4. Operating business segments
- 10.4.5. Product portfolio
- 10.4.6. Key strategic moves and developments
10.5. Amgen Inc.
- 10.5.1. Company overview
- 10.5.2. Key Executives
- 10.5.3. Company snapshot
- 10.5.4. Operating business segments
- 10.5.5. Product portfolio
- 10.5.6. Business performance
10.6. Empatica
- 10.6.1. Company overview
- 10.6.2. Key Executives
- 10.6.3. Company snapshot
- 10.6.4. Operating business segments
- 10.6.5. Product portfolio
- 10.6.6. Key strategic moves and developments
10.7. Sonde Health, Inc.
- 10.7.1. Company overview
- 10.7.2. Key Executives
- 10.7.3. Company snapshot
- 10.7.4. Operating business segments
- 10.7.5. Product portfolio
10.8. Clario
- 10.8.1. Company overview
- 10.8.2. Key Executives
- 10.8.3. Company snapshot
- 10.8.4. Operating business segments
- 10.8.5. Product portfolio
10.9. Feel Therapeutics
- 10.9.1. Company overview
- 10.9.2. Key Executives
- 10.9.3. Company snapshot
- 10.9.4. Operating business segments
- 10.9.5. Product portfolio
- 10.9.6. Key strategic moves and developments
10.10. Brainomix
- 10.10.1. Company overview
- 10.10.2. Key Executives
- 10.10.3. Company snapshot
- 10.10.4. Operating business segments
- 10.10.5. Product portfolio

デジタルバイオマーカー市場：タイプ別、用途別、診療行為別、エンドユーザー別：世界の機会分析と産業予測、2023～2032年

Digital Biomarkers Market By Type, By Application, By Clinical Practice, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章デジタルバイオマーカー市場：タイプ別

第5章デジタルバイオマーカー市場：用途別

第6章デジタルバイオマーカー市場：診療行為別

第7章デジタルバイオマーカー市場：エンドユーザー別

第8章デジタルバイオマーカー市場：地域別

第9章競争情勢

第10章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Application

By Clinical Practice

By End User

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: DIGITAL BIOMARKERS MARKET, BY TYPE

CHAPTER 5: DIGITAL BIOMARKERS MARKET, BY APPLICATION

CHAPTER 6: DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE

CHAPTER 7: DIGITAL BIOMARKERS MARKET, BY END USER

CHAPTER 8: DIGITAL BIOMARKERS MARKET, BY REGION

CHAPTER 9: COMPETITIVE LANDSCAPE

CHAPTER 10: COMPANY PROFILES

デジタルバイオマーカー市場：タイプ別、用途別、診療行為別、エンドユーザー別：世界の機会分析と産業予測、2023～2032年

Digital Biomarkers Market By Type, By Application, By Clinical Practice, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 デジタルバイオマーカー市場：タイプ別

第5章 デジタルバイオマーカー市場：用途別

第6章 デジタルバイオマーカー市場：診療行為別

第7章 デジタルバイオマーカー市場：エンドユーザー別

第8章 デジタルバイオマーカー市場：地域別

第9章 競争情勢

第10章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Application

By Clinical Practice

By End User

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: DIGITAL BIOMARKERS MARKET, BY TYPE

CHAPTER 5: DIGITAL BIOMARKERS MARKET, BY APPLICATION

CHAPTER 6: DIGITAL BIOMARKERS MARKET, BY CLINICAL PRACTICE

CHAPTER 7: DIGITAL BIOMARKERS MARKET, BY END USER

CHAPTER 8: DIGITAL BIOMARKERS MARKET, BY REGION

CHAPTER 9: COMPETITIVE LANDSCAPE

CHAPTER 10: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章デジタルバイオマーカー市場：タイプ別

第5章デジタルバイオマーカー市場：用途別

第6章デジタルバイオマーカー市場：診療行為別

第7章デジタルバイオマーカー市場：エンドユーザー別

第8章デジタルバイオマーカー市場：地域別

第9章競争情勢

第10章企業プロファイル